Vogelberg, C.
Brüggenjürgen, B.
Richter, H.
Jutel, M.
Funding for this research was provided by:
Technische Universität Dresden
Article History
Received: 4 August 2020
Accepted: 13 November 2020
First Online: 17 December 2020
Conflict of interest
: C. Vogelberg has received lecture or consulting fees from ALK-Abelló, Allergopharma, Allergy Therapeutics, AstraZeneca, Boehringer Ingelheim, Bencard Allergy, DBV Technologies, LETI Pharma, Novartis Pharma and Sanofi Aventis. M. Jutel has received lecture or consulting fees from ALK-Abelló, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, LETI Pharma, Biomay, HAL Allergy, Astra-Zeneca, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, and Chiesi. B. Brüggenjürgen reports grants from Allergopharma during the conduct of the study. H. Richter declares that he has no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.